Brought to you by 
CTI and Spectrum form JV for marketing of Zevalin; ended
31 Jan 2012
Executive Summary
Cancer companies Cell Therapeutics and Spectrum Pharmaceuticals have formed a joint venture, RTI Oncology, whose sole business will be to develop and market CTI's non-Hodgkin's lymphoma treatment Zevalin (ibritumomab tiuxetan) in the US.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CTI and Spectrum form JV for marketing of Zevalin; ended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice